Rubraca
- Product NDC
- 82154-0784
- 11-digit product format
- 821540784
- Labeler code
- 82154
- Product ID
- 82154-0784_473a8026-e822-2a9e-e063-6294a90a5c06
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- rucaparib
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- pharmaand GmbH
- Application
- NDA209115
- Marketing category
- NDA
- Marketing start
- 2017-05-01
- Substance
- RUCAPARIB CAMSYLATE
- Active strength
- 250 mg/1
- Pharmacologic classes
- Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N209115-001 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | |
| N209115-002 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | |
| N209115-003 | RUBRACA | RUCAPARIB CAMSYLATE | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N209115-001 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-001 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-001 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-001 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-001 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-001 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-001 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-001 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-001 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | |
| N209115-001 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-001 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-001 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-002 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | |
| N209115-002 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | |
| N209115-002 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-002 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-002 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | |
| N209115-002 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-002 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | |
| N209115-002 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-002 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-002 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2012 | 2017-05-09 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2273 | 2017-05-09 | |
| N209115-003 | 8071579 | 2027-08-12 | U-2830 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2012 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2273 | 2017-05-09 | |
| N209115-003 | 8143241 | 2027-08-12 | U-2830 | 2017-05-09 | |
| N209115-003 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | |
| N209115-003 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2017-05-09 | |
| N209115-003 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2017-05-09 | |
| N209115-003 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | |
| N209115-003 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2012 | 2017-05-09 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2273 | 2017-05-09 | |
| N209115-003 | 8859562 | 2031-08-04 | U-2830 | 2017-05-09 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | |
| N209115-003 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | |
| N209115-003 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 |
Orange Book exclusivity#
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N209115-001 | I-982 | 2028-12-17 |
| N209115-002 | I-982 | 2028-12-17 |
| N209115-003 | I-982 | 2028-12-17 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N209115-002 | RUBRACA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2016-12-19 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N209115-003 | RUBRACA | EQ 250MG BASE | TABLET / ORAL | RLD | 2017-05-01 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N209115-001 | RUBRACA | EQ 200MG BASE | TABLET / ORAL | RLD | 2016-12-19 | 301d65b070ca… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8071579 | 2027-08-12 | U-2273 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8071579 | 2027-08-12 | U-2012 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8071579 | 2027-08-12 | U-2830 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8143241 | 2027-08-12 | U-2012 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8143241 | 2027-08-12 | U-2273 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8143241 | 2027-08-12 | U-2830 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 10278974 | 2031-02-10 | Drug product | 2019-06-04 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8754072 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 9045487 | 2031-02-10 | Drug substance, Drug product | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 9861638 | 2031-02-10 | U-2012 | 2018-02-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 9861638 | 2031-02-10 | U-2273 | 2018-02-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8859562 | 2031-08-04 | U-2273 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8859562 | 2031-08-04 | U-2012 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 8859562 | 2031-08-04 | U-2830 | 2016-12-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 10130636 | 2035-08-17 | U-2101 | 2018-12-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 10130636 | 2035-08-17 | U-2273 | 2018-12-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 10130636 | 2035-08-17 | U-2012 | 2018-12-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 10130636 | 2035-08-17 | U-2830 | 2018-12-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | 9987285 | 2035-08-17 | Drug product | 2018-06-28 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-003 | 8071579 | 2027-08-12 | U-2012 | 2017-05-09 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N209115-003 | 8071579 | 2027-08-12 | U-2273 | 2017-05-09 | 84e616aacf4f… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N209115-001 | I-982 | 2028-12-17 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N209115-002 | I-982 | 2028-12-17 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N209115-003 | I-982 | 2028-12-17 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N209115-001 | I-982 | 2028-12-17 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N209115-002 | I-982 | 2028-12-17 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N209115-003 | I-982 | 2028-12-17 | caaa826d4ba7… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N209115-001 | ODE-168 | 2025-04-06 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N209115-002 | ODE-168 | 2025-04-06 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N209115-003 | ODE-168 | 2025-04-06 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N209115-001 | ODE-168 | 2025-04-06 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N209115-002 | ODE-168 | 2025-04-06 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N209115-003 | ODE-168 | 2025-04-06 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N209115-001 | ODE-168 | 2025-04-06 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N209115-002 | ODE-168 | 2025-04-06 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N209115-003 | ODE-168 | 2025-04-06 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N209115-001 | ODE-168 | 2025-04-06 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N209115-002 | ODE-168 | 2025-04-06 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N209115-003 | ODE-168 | 2025-04-06 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N209115-001 | ODE-168 | 2025-04-06 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N209115-002 | ODE-168 | 2025-04-06 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N209115-003 | ODE-168 | 2025-04-06 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N209115-001 | ODE-168 | 2025-04-06 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N209115-002 | ODE-168 | 2025-04-06 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N209115-003 | ODE-168 | 2025-04-06 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N209115-001 | ODE-168 | 2025-04-06 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N209115-002 | ODE-168 | 2025-04-06 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N209115-003 | ODE-168 | 2025-04-06 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N209115-001 | ODE-168 | 2025-04-06 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N209115-002 | ODE-168 | 2025-04-06 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N209115-003 | ODE-168 | 2025-04-06 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N209115-001 | ODE-168 | 2025-04-06 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | N209115-002 | ODE-168 | 2025-04-06 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | N209115-003 | ODE-168 | 2025-04-06 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N209115-001 | ODE-168 | 2025-04-06 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N209115-002 | ODE-168 | 2025-04-06 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N209115-003 | ODE-168 | 2025-04-06 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N209115-001 | ODE-168 | 2025-04-06 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N209115-002 | ODE-168 | 2025-04-06 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N209115-003 | ODE-168 | 2025-04-06 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N209115-001 | ODE-168 | 2025-04-06 | 1e350fbaab3a… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Rubraca
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| RUCAPARIB CAMSYLATE | 250 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 41AX9SJ8KO | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 0295d202-1cfe-7659-e063-6294a90a476e | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 594e2c86-3079-4e6e-96c9-48f7a8afc78d | Product name | 1 | 20230718 |
| f430e54b-e9d6-4b78-bc11-c25cef55f87c | Product name | 1 | 20170302 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 82154-0784-1 | Rubraca | 60 in 1 BOTTLE | TABLET, FILM COATED | 60 | 19 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 82154-0784-1 | EA - Each | 82154-0784 | 0c9bd866-6a39-4f14-bb49-460f7d2f7027 | 1 | 2024-10-04 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 82154-0784 | RUBRACA (RUCAPARIB) TABLET, FILM COATED [PHARMAAND GMBH] | 18 | Current NDC, 1 package rows | 20250130_0295d202-1cfe-7659-e063-6294a90a476e.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Rubraca | RUCAPARIB | pharmaand GmbH | 0295d202-1cfe-7659-e063-6294a90a476e | 2025-12-31 | Warnings, Adverse reactions | 209115 NDA209115 82154-0784 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 1862595 | Rubraca 200 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921589 | Rubraca 250 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862590 | Rubraca 300 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862593 | rucaparib 200 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921587 | rucaparib 250 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862584 | rucaparib 300 MG Oral Tablet | PSN | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862595 | rucaparib 200 MG Oral Tablet [Rubraca] | SBD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921589 | rucaparib 250 MG Oral Tablet [Rubraca] | SBD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862590 | rucaparib 300 MG Oral Tablet [Rubraca] | SBD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862593 | rucaparib 200 MG Oral Tablet | SCD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921587 | rucaparib 250 MG Oral Tablet | SCD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862584 | rucaparib 300 MG Oral Tablet | SCD | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862595 | Rubraca (as rucaparib camisylate) 200 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921589 | Rubraca (as rucaparib camisylate) 250 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862590 | Rubraca (as rucaparib camisylate) 300 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862595 | Rubraca 200 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921589 | Rubraca 250 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862590 | Rubraca 300 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1921587 | rucaparib (as rucaparib camisylate) 250 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862593 | rucaparib (as rucaparib camsylate) 200 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
| 1862584 | rucaparib (as rucaparib camsylate) 300 MG Oral Tablet | SY | 0295d202-1cfe-7659-e063-6294a90a476e | 19 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 82154-0784-1 | 82154078401 | 60 TABLET, FILM COATED in 1 BOTTLE (82154-0784-1) | 2017-05-01 | No | No | Current |